King's College London

What King's College London does

King's College London is a public research university established by royal charter in 1829, headquartered on the Strand in central London and operating across five London campuses (Strand, Guy's, Denmark Hill, St Thomas', Bush House, and 22 Kingsway). A founding member of the Russell Group, the university offers over 180 undergraduate, postgraduate taught, and research degree programs across nine faculties (Arts & Humanities, Business, Dentistry/Oral & Craniofacial Sciences, Law, Life Sciences & Medicine, Natural/Mathematical & Engineering Sciences, Nursing/Midwifery/Palliative Care, Psychiatry/Psychology/Neuroscience, and Social Science & Public Policy), serving roughly 40,000 students and ranking 31st globally in the QS World University Rankings 2026. Revenue derives from a diversified mix: tuition (with international fees ranging from approximately £20,000 to over £40,000 per year), competitive research grants from UKRI, Wellcome, NIHR, ARIA, EU/IHI and industry, clinical services delivered through King's Health Partners (Guy's and St Thomas', South London and Maudsley, and Royal Brompton and Harefield NHS trusts), philanthropic donations, and technology licensing and spin-outs. The institution is also the UK base for a dense network of strategic industry and government partnerships spanning NHS providers, GE HealthCare, Google Quantum AI/NQCC, AviadoBio, Hinduja Foundation, deepc, and OneLondon, among others.

The university's research and technology footprint is unusually broad for a higher education institution, spanning AI/machine learning, quantum computing, medical imaging, genomics, neuroscience, biomedical engineering, and digital health. King's has developed several proprietary research platforms: FLIP, an open-source federated learning platform enabling privacy-preserving healthcare AI training; HypoxiCAR, a tumour-activated CAR-T platform for solid cancers commercialized via spin-out Korecyte Bio; vMiX, an RNAi gene silencing platform exclusively licensed to AviadoBio; SMARTdrugs, a radiotheranostic platform backed by nearly €4 million from the European Innovation Council; and xMemory, a hierarchical AI agent memory architecture developed with The Alan Turing Institute. King's hosts multiple major 2026 initiatives including the COMPASS cardio-oncology AI consortium (€50.5M, EU IHI), epiPRIME respiratory virus prophylaxis (part of £5.79M ARIA award), the NIHR Policy Research Unit in Palliative and End of Life Care (£2M), and the Longitude Prize on ALS Discovery Awards. Ancillary revenue and translational mechanisms include the King's Start-up Accelerator, Innovation Development Award (up to £50K per project), SPARK Innovation Fund, and AI Centre for Value-Based Healthcare.

Operationally, King's is governed by its Council with the Vice-Chancellor & President (Shitij Kapur) and a senior team including the Senior Vice Presidents (Academic and Operations) and Vice-President (Finance); it operates as a non-profit charity registered with OfS. In May 2026 the university signed a merger agreement with Cranfield University, expected to complete by August 2027, which would expand the combined entity to approximately 47,000 students (UK's second-largest mainstream provider), expand capability into engineering, AI, defence, energy, manufacturing, and climate research, and is projected to lift the QS ranking to 21st. The institution is signatory to the Concordat to Support Research Integrity, UK Reproducibility Network, Sorbonne Declaration, and complies with UK GDPR, MHRA, HTA, and Trusted Research requirements; it is also pursuing WCAG 2.2 AA accessibility compliance across legacy web pages by December 2026.

Name

King's College London

Legal name

King's College London

Website

https://kcl.ac.uk

Company type

Private

Founded year

1829

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

King's College London is a Russell Group public research university founded in 1829, delivering undergraduate, postgraduate, and doctoral programs across nine faculties to roughly 40,000 students from London campuses, with revenue from tuition, NHS-linked clinical services via King's Health Partners, competitive research grants, and technology licensing, and a pending 2027 merger with Cranfield University.

Ownership category

akta.pro rank

Product category

Higher Education

NAICS

Colleges, Universities, and Professional Schools (611310)

SIC

Services-Educational Services (8200)

akta.pro primary industry

Public Research Universities with Comprehensive Graduate & Professional Schools (EDAHAAAF)

akta.pro secondary industries

Public Research Universities with Multi-Campus Systems (EDAHAAAI), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC)

Keywords

• Higher education
• University research
• Postgraduate programs
• Healthcare AI
• Technology licensing

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain, Others

Revenue model

1. Tuition Fees: King's generates primary revenue from tuition fees for undergraduate, postgraduate taught, and research programs. International students pay higher fees ranging from approximately £9,250 to over £40,000 per year depending on program and student origin.
2. Research Grants and Contracts: The university receives substantial funding from research councils (UKRI, Wellcome, NIHR, European Union), government agencies, and industry partners for sponsored research programs.
3. Healthcare Services: Through King's Health Partners, the university provides clinical services in partnership with NHS trusts including Guy's and St Thomas' NHS Foundation Trust and South London and Maudsley NHS Foundation Trust.
4. Technology Licensing: Revenue from licensing proprietary technologies and platforms such as the vMiX RNAi gene silencing platform to biotech companies, and spinout companies like Korecyte Bio.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

King's College London is a public research university that delivers undergraduate, postgraduate taught, and postgraduate research degree programs across nine faculties, alongside clinical healthcare services delivered through King's Health Partners. The university operates research and innovation programs that develop proprietary platforms in healthcare AI, gene therapy, and radiotheranostics, commercialized through licensing agreements and spinout companies.

Product overview

King's College London operates as a comprehensive research university offering educational services across undergraduate, postgraduate taught, and research programmes. The institution functions as a platform-plus-services model combining academic education with research commercialization through spin-outs, technology platforms, and innovation programmes. Core offerings include undergraduate and postgraduate degree programmes across arts, humanities, sciences, engineering, medicine, law, and business. Technology products include FLIP (federated learning platform for healthcare AI), LearnLens (AI assessment with AQA), SMARTdrugs (radiotheranostic cancer platform), HypoxiCAR (CAR-T therapy via Korecyte Bio spin-out), and vMiX (gene silencing via AviadoBio license). Innovation services encompass the Start-up Accelerator, Innovation Development Award (£50K funding), SPARK Innovation Fund, and AI Centre for Value-Based Healthcare. Scholarship programmes include Hinduja-King's Health Partners Academy and Sanctuary Programme for displaced persons. Research infrastructure includes partnerships with NHS trusts, GE HealthCare MRI installations, and participation in consortia like COMPASS (€50M cardio-oncology) and various quantum computing initiatives.

Differentiator

Problem solved

Functional benefit

Brands

• FLIP: Open-source federated learning platform for healthcare AI development enabling secure AI collaboration across health systems while keeping patient data within institutional control
• HypoxiCAR
• SMARTdrugs
• COMPASS

Products and services

• Undergraduate Degree Programmes Over 180 bachelor's degree courses across nine faculties, offered to domestic and international students enrolling through UCAS and the King's online application system.
• Postgraduate Taught Programmes Master's degree programmes across all faculties including specialised degrees in healthcare technology, medical innovation, business, and the humanities, delivered to postgraduate students.
• Postgraduate Research Programmes PhD and research degree programmes across all disciplines, providing students with access to research facilities and academic supervision.
• Professional Education

Quantifiable outcome

• Top 40 globally, ranked 31st in QS World University Rankings
• +3 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability45 records

Feature5 records

Partnerships

18 partnerships are on record, tiered core, minor and major.

• ARIA (epiPRIME)coreStrategic or Co-development Partner · 26 June 2026King's researchers received £227,000 as part of £5.79 million ARIA-funded epiPRIME project focused on developing broad prophylactic strategies against respiratory viruses through epigenetic engineering of the innate immune system.
• Asthma+Lung UKminorStrategic or Co-development Partner · 18 June 2026Feasibility study funded by Asthma+Lung UK to assess whether laughter yoga could help people with chronic lung conditions like bronchiectasis clear their airways and manage symptoms.
• AviadoBiocoreOEM/ Whitelabel/ Licensing Partner · 16 June 2026Expanded license agreement granting AviadoBio exclusive rights to apply vMiX RNAi gene silencing platform across all human therapeutic areas including cardiovascular disease, nephrology, oncology, and beyond original 2020 neurological disease focus. Company plans clinical trials for vMiX-enabled programs in 2026.
• Norwegian Ministry for Research and Higher EducationminorStrategic or Co-development Partner · 12 June 2026Norwegian Minister Sigrun Aasland visited King's for roundtable on quantum technologies, exploring healthcare and defence applications, commercialization of quantum research, and government-university-industry collaboration. Visit supports Norway's development of national quantum strategy.
• National Maritime FoundationminorStrategic or Co-development Partner · 4 June 2026MoU between King's College London and National Maritime Foundation for a Regional Maritime Security Centre of Excellence, signed during India-UK ministerial meetings under the CETA trade deal and India-UK Vision 2035 framework.
• Google Quantum AI / National Quantum Computing CentrecoreStrategic or Co-development Partner · 28 May 2026King's researchers led by Dr. Eleanor Crane awarded access to Google's next-generation Willow quantum processor through joint initiative with NQCC, following progression as finalists in Google XPRIZE competition. Research focuses on mathematical analogies for neurons and quantum mechanical effects.
• Cell and Gene Therapy CatapultcoreStrategic or Co-development Partner · 26 May 2026Cell and Gene Therapy Catapult provided investment and support for spinout Korecyte Bio Ltd developing the HypoxiCAR platform for solid tumour CAR-T therapy. The support was provided through the Innovate UK Cross-Catapult Investment Pilot to advance the novel CAR-T platform toward clinical readiness.
• Hinduja FoundationcoreGTM or Marketing Partner · 26 May 2026Partnership offering full four-year PhD studentships in healthcare technologies and one-year MSc MedTech Innovation and Entrepreneurship programme for Indian students. The collaboration aims to improve healthcare outcomes in both countries through talent development.
• Longitude Prize (ALS Programme)coreStrategic or Co-development Partner · 15 May 2026King's researchers part of three teams awarded £100,000 Discovery Awards each as part of £7.5 million Longitude Prize on ALS programme funding AI-based approaches to transform drug discovery for amyotrophic lateral sclerosis.
• Prima Mente (AI biology company)coreStrategic or Co-development Partner · 15 May 2026King's researcher Dr Jemeen Sreedharan collaborating with Prima Mente on AI biology approaches for ALS drug discovery as part of Longitude Prize on ALS programme.
• Project MinEcoreStrategic or Co-development Partner · 15 May 2026King's researcher Dr Ahmad Al Khleifat leading Project MinE team awarded Discovery Award as part of Longitude Prize on ALS programme for AI-based drug discovery approaches.
• ALS Precision Discovery ConsortiumcoreStrategic or Co-development Partner · 15 May 2026Professor Alfredo Iacoangeli leading ALS Precision Discovery Consortium awarded Discovery Award for AI approaches to transform drug discovery for amyotrophic lateral sclerosis.
• Nigerian Army Resource CentreminorStrategic or Co-development Partner · 1 May 2026Six-year collaboration between Nigerian Army and King's College London facilitating access to military education and supporting ongoing reforms for developing a professional and combat-ready force. Collaboration addresses emerging digital information threats.
• GE HealthCarecoreStrategic or Co-development Partner · 26 March 2026GE HealthCare serves as industry lead in COMPASS consortium, a five-year EU-funded initiative with €50.5 million budget and over 60 partners focused on cardio-oncology care. King's College London provides academic leadership and scientific coordination. The partnership includes installation of investigational MAGNUS head-only MR scanner at King's for neuroscience research.
• OneLondoncoreTechnology or Integration · 2 March 2026Partnership in development of FLIP federated learning platform with OneLondon and Flower Labs, designed to accelerate AI innovation in the NHS while maintaining privacy standards and reducing vendor dependency.
• deepccoreTechnology or Integration · 27 February 2026deepc collaborated with King's AI Centre and Guy's and St Thomas' NHS Foundation Trust to develop FLIP, an open-source federated learning platform enabling secure AI collaboration across health systems while keeping patient data within institutional control.
• University of Zagreb (ToxiCode)majorStrategic or Co-development Partner · 20 February 2026King's participates in ToxiCode collaboration led by University of Zagreb, securing €3 million World Bank funding over three years for AI-driven drug discovery using venom-derived peptides. King's receives €120,000 service contract with Professor Paul Long leading field expeditions for venom sample collection.
• European Innovation Council (SMARTdrugs)coreStrategic or Co-development Partner · 29 May 2024European Innovation Council funding of nearly €4 million for SMARTdrugs platform development - a radiotheranostic platform for diagnosing and treating aggressive cancers including lung and brain tumours, with international partners in Munich, Zurich, San Sebastian, and Utrecht.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• University College London (UCL): UCL is a London-based Russell Group public research university with a similarly broad academic portfolio, comparable size, and overlapping strengths in medicine, law, and sciences. It is the most direct London competitor for students, faculty, and research funding.
• Imperial College London: Imperial is a Russell Group London university focused on science, engineering, medicine, and business, directly competing with King's for STEM/medical students, research grants, and clinical partnerships including NHS trusts.
• London School of Economics and Political Science (LSE): LSE is a London-based Russell Group specialist university in social sciences and public policy, directly comparable to King's Faculty of Social Science & Public Policy and competing for the same international postgraduate cohorts.
• University of Oxford: Oxford is a Russell Group research-intensive university with comparable breadth across humanities, sciences, medicine, and law; it competes for top students, faculty, and global rankings and is a benchmark for King's position.
• University of Cambridge: Cambridge is a Russell Group research-intensive university with overlapping faculties, similar research depth in medicine and sciences, and a comparable international brand that competes for the same talent pool and global rankings.
• University of Edinburgh: Edinburgh is a Russell Group research university with comparable size, broad academic portfolio, and medical school, making it a peer competitor in UK research rankings and international student recruitment.
• University of Manchester: Manchester is a large Russell Group public research university with similar scale, medical/health research strengths, and broad faculty offerings, providing a useful comparator for research output and student volume.

Broad incumbents

• Stanford University: Stanford is a global Top 5 research university with comparable strengths in medicine, AI, and spinout creation; it represents the upper benchmark for research impact and innovation commercialisation that King's aspires to in selected domains.
• Massachusetts Institute of Technology (MIT): MIT is a global leader in STEM, AI, and applied research with a major teaching hospital; relevant peer for benchmarking King's COMPASS consortium work, AI Centre activity, and engineering ambitions post-Cranfield merger.
• ETH Zurich: ETH Zurich is a leading European public research university with strengths in engineering, AI, and natural sciences; a useful comparator for the post-Cranfield engineering/AI ambition and for European research consortium leadership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/kingscollegelon
• YouTubeyoutube.com/user/kingscollegelondon
• Facebookfacebook.com/kingscollegelondon
• LinkedInlinkedin.com/company/7198
• Instagraminstagram.com/lifeatkings
• TikToktiktok.com/@kingscollegelondon

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about King's College London